Psoriasis Vulgaris Clinical Trial
— APRESCALPOfficial title:
A Phase 4 Multicenter, Randomized, Placebo-controlled Study Evaluating the Effect of Apremilast on Pruritus and Quality of Life of Patients With Moderate-to-severe Scalp Psoriasis
A phase 4 multicenter, randomized, placebo-controlled Study evaluating the Effect of Apremilast on Pruritus and Quality of Life of Patients with moderate-to-severe Scalp Psoriasis
Status | Not yet recruiting |
Enrollment | 90 |
Est. completion date | June 2020 |
Est. primary completion date | December 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion criteria: 1. Adult (>18yrs); 2. Signed informed consent 3. Clinical diagnosis of chronic plaque psoriasis for at least 3 months as determined by the subject's medical history and confirmation of diagnosis through physical examination by the Investigator; 4. Psoriatic lesions with DLQI >10 and involvement of >20% of the scalp and pruritus with a VAS score of > 50 (0-100); 5. Candidate for systemic therapy; 6. Females who are of child-bearing potential should be practicing birth control throughout the study and for 70 days after the last dose of study drug; 7. Subject is judged to be in good health as determined by the Investigator based upon the results of medical history, laboratory profile and physical examination. 8. Creatinine < 80 umol/l at Inclusion Exclusion criteria: 1. Erythrodermic Ps, medication-induced or medication-exacerbated Ps or new onset guttate Ps or other skin conditions at the time of the screening visit (e.g. eczema) that would interfere with evaluations of the effect of the investigational product on Ps; 2. Use of any anti-psoriatic therapy last administered less than 4 weeks of start of study drug such as 1. Three months or 5 PK half-lives, whichever is longer, for biologics tumor necrosis factor (TNF) antagonists, interleukin (IL) 12/23/17 inhibitors or other biologic drugs 2. 4 weeks for immunosuppressive / -modulating drugs including cyclosporine A, methotrexate, azathioprine, mycophenolate mofetil, fumaric acid esters, retinoids, JAK inhibitors, corticosteroids, any other experimental drug, etc. 3. Topical medications (eg. Corticosteroids) except coal tar shampoo, and/or salicylic acid scalp preparations on scalp lesions. 4. 4 weeks for phototherapy (ie, UVB, PUVA). 3. Infection(s) requiring treatment with intravenous (IV) anti-infectives within 30 days prior to the Baseline visit or oral anti-infectives within 14 days prior to the Baseline visit; 4. Positive serology for hepatitis B, hepatitis C, HIV indicating acute or chronic infection; 5. Chronic recurring bacterial infections or active TB; 6. Positive pregnancy test at Screening or at the Baseline visit; 7. Female subjects who are pregnant or breast-feeding or considering becoming pregnant during the study; 8. History of clinically significant alcohol or drug abuse in the last 12 months; 9. Known hypersensitivity to the excipients of Otezla® as stated in the label; 10. Subject is considered by the Investigator, for any reason, to be an unsuitable candidate for the study. 11. Prior history of suicide attempt at any time in the subject's life time prior to signing the informed consent and randomization, or major psychiatric illness requiring hospitalization within the last 3 years prior to signing the informed consent. |
Country | Name | City | State |
---|---|---|---|
Switzerland | Inselspital | Bern | |
Switzerland | CHUV | Lausanne | |
Switzerland | KSSG | Saint Gallen | SG |
Switzerland | Department of Dermatology, University Hospital Zurich | Zurich |
Lead Sponsor | Collaborator |
---|---|
University of Zurich |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Scalp VAS Pruritus assessment | Pruritus VAS Scale (0 - 100) | Weeks 16 | |
Secondary | Scalp VAS Pruritus assessment | Pruritus VAS Scale (0 - 100) | Weeks 0, 4, 32, 52 | |
Secondary | % BSA | Body surface area | Weeks 0, 4, 16, 32, 52 | |
Secondary | % BSA of scalp | Body surface area of scalp | Weeks 0, 4, 16, 32, 52 | |
Secondary | PrecisePASI | Psoriasis Area and Severity Index, modified to measure in percentages | Weeks 0, 4, 16, 32, 52 | |
Secondary | PGA | Physicians Global Assessment (0 - 5) | Weeks 0, 4, 16, 32, 52 | |
Secondary | Scalp-PGA | Physicians Global Assessment of the Scalp (0 - 5) | Weeks 0, 4, 16, 32, 52 | |
Secondary | DLQI | Skin related Quality of life (0 to 30) | Weeks 0, 4, 16, 32, 52 | |
Secondary | Scalpdex | 23 items related to scalp symptoms | Weeks 0, 4, 16, 32, 52 | |
Secondary | PSSI | Psoriasis score measuring intensity on the scalp | Weeks 0, 4, 16, 32, 52 | |
Secondary | VAS pruritus assessment | Pruritus VAS Scale (0 - 100) | Weeks 0, 4, 16, 32, 52 | |
Secondary | EQ-5D | Health-related Quality of Life Instrument | Weeks 0, 4, 16, 32, 52 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03669757 -
Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis
|
Phase 1 | |
Completed |
NCT03614078 -
A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT03584360 -
Role of Topical Treatments in the Modulation of Skin Microbiome in Psoriatic Skin
|
Phase 2 | |
Recruiting |
NCT04994951 -
Pilot Study of Traditional Chinese Medicine (Qing-Re-Liang-Xue Decoction) as Complementary Medicine for Psoriasis Vulgaris of Blood-heat Syndrome.
|
Phase 2 | |
Completed |
NCT02888236 -
LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris
|
Phase 2 | |
Completed |
NCT02533973 -
Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population
|
Phase 4 | |
Completed |
NCT02193815 -
A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis
|
Phase 1 | |
Completed |
NCT01946386 -
A Vasoconstriction Study With LEO 90100
|
Phase 1 | |
Completed |
NCT02004847 -
Blue Light for Treating Psoriasis Vulgaris
|
N/A | |
Recruiting |
NCT01443338 -
Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Psoriasis Vulgaris - CHINA201002016-2
|
Phase 4 | |
Completed |
NCT01188928 -
LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)
|
Phase 3 | |
Completed |
NCT00764751 -
Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris
|
Phase 2 | |
Completed |
NCT00236171 -
Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test
|
N/A | |
Completed |
NCT04541329 -
Predicting Inflammatory Skin Disease Response to IL-23 Blockade
|
Phase 4 | |
Completed |
NCT06064084 -
Incretin Effect in Patients With Psoriasis and Controls
|
||
Not yet recruiting |
NCT06398106 -
Proactive TDM Versus Standard Use of Biologics in Psoriasis
|
Phase 4 | |
Recruiting |
NCT05892640 -
Low-Salt Diet Effect on Th17-Mediated Inflammation and Vascular Reactivity in Psoriasis
|
N/A | |
Recruiting |
NCT05390515 -
Psoriatic Immune Response to Tildrakizumab
|
Phase 4 | |
Recruiting |
NCT04950218 -
The Psoriasis Echo Study
|
||
Completed |
NCT05184348 -
Plexin B2 Gene Expression and Polymorphisms in Psoriasis
|
Phase 1 |